Relacorilant for insulin resistance

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Nov 2026: Trial registered, NCT07925801

The trials

NCT07925801: Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion

State
Not started
Phase
Phase 1 and Phase 2
People
34 planned
Started
1 Dec 2026
Primary completion
15 Dec 2028
Arms
Study Investigational Drug Group
Results
None posted
  1. 9 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Lifyorli, Relacorilant 150 mg.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.